TrialThe Lancet. Oncology2017

Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.

Hussein A Tawbi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.